ROCHE HOLDING popularity and ROCHE HOLDING trends

* Progression-free survival of 7.4 months * Much lower incidence of squamous cell cancer By Deena Beasley May 16 (Reuters) - Two drugs being developed by GlaxoSmithKline Plc - each designed to block different pathways used by cancer cells - have been shown in a small clinical trial to curb melanoma with fewer side effects than current therapies. ...

GENEVA (AP) -- Swiss drug maker Roche Holding AG has ended development of a cholesterol drug that it had hoped could achieve blockbuster status....

Roche Holding decided not to extend beyond Friday its $51-a-share offer to buy U.S. diagnostics company Illumina.

ZURICH (Reuters) - Roche Holding AG stepped up its charm offensive towards Illumina shareholders as it battles to take over the U.S. gene sequencing company, telling them its increased $6.7 billion...

ROCHE HOLDING has extended its $5.7 billion hostile takeover offer for Illumina for a second time, setting up a showdown next month at the annual meeting of the US maker of gene-mapping tools.

Roche Holding extended its $5.7 billion cash bid for US gene decoder Illumina for a second time as the Swiss pharmaceutical firm sticks to its tried and tested M&A strategy.

Roche Holding AG said the fake Avastin drug contained starch, salt and cleaning solvents, but none of the drug’s active ingredient

(Reuters) - Roche Holding AG is offering $5.7 billion in cash to buy U.S. gene sequencing company Illumina Inc in a hostile takeover bid that marks a major play by the Swiss drugmaker into the gene technology field.

The fate of Avastin as a breast cancer treatment has finally been decided. And U.S regulators did not come down on the side of Swiss drug maker Roche Holding (RHHBY). The FDA announced today it is removing the approval of Avastin as a treatment for metastatic breast cancer because it isn’t safe and effective for [...]